Don’t let the high cost of brand specialty type 2 diabetes therapy disrupt your treatment. We help eligible patients access Avandia (rosiglitazone) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
The Avandia Prescription Assistance Program is a manufacturer-sponsored initiative that provides Avandia at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for type 2 diabetes patients who are uninsured or underinsured.
Navigating the program on your own means dealing with eligibility verification, prescriber coordination, prior-authorization documentation, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens (brand) | ~$310.00 | Save ~$240/mo |
| CVS Pharmacy (brand) | ~$330.00 | Save ~$260/mo |
| Walmart (brand) | ~$250.00 | Save ~$180/mo |
| Costco (brand) | ~$240.00 | Save ~$170/mo |
| Generic rosiglitazone | ~$50.00 | Generic — lower |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Patient Assistance Program is free to apply for and provides Avandia at no medication cost if approved. Our $69.95/month service covers full advocacy. With generic rosiglitazone available — and generic pioglitazone often the preferred TZD due to a better cardiovascular profile — we’ll help your provider determine the best path.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Avandia:
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Avandia assistance.
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Avandia (rosiglitazone) is a once-daily thiazolidinedione (TZD) used to improve glycemic control in type 2 diabetes. It works primarily by improving insulin sensitivity in peripheral tissues — muscle, fat, and liver — rather than by stimulating insulin secretion.
How Avandia Works:
Rosiglitazone acts as an agonist for the nuclear receptor PPAR-γ, which controls genes responsible for glucose and lipid metabolism. By activating this receptor, the medication restores insulin sensitivity in the liver, fat, and muscle tissues. This process enhances glucose uptake and reduces hepatic glucose output without causing hypoglycemia when used as a monotherapy.
Form and use:
Marketed under the brand name Avandia, this medication is administered orally as a tablet once or twice daily, regardless of food intake. It is available in strengths of 2, 4, and 8 mg, with the maximum therapeutic effect typically developing over two to three months. Clinical progress is tracked by monitoring HbA1c levels every three months.
Generic availability:
While generic rosiglitazone is a cost-effective alternative to Avandia, pioglitazone (Actos) is often preferred within the same drug class for cardiovascular reasons. Additionally, newer agents like SGLT2 inhibitors and GLP-1 receptor agonists are now favored in modern guidelines due to their heart and kidney benefits. Despite the clinical advantages of newer drugs, the lower cost of generics remains a significant factor for many patients.
Warnings:
The medication carries a boxed warning for congestive heart failure and is contraindicated for patients with NYHA Class III or IV heart failure. Significant side effects include weight gain, edema, increased fracture risk in women, and potential myocardial ischemia. Other rare but serious concerns involve hepatotoxicity, macular edema, and a possible risk of bladder cancer.
Brand Avandia costs approximately $230–$330 per 30-day supply. Generic rosiglitazone is substantially cheaper. Through AffordMyPrescriptions, qualifying patients receive Avandia at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Earlier studies raised concerns that rosiglitazone might increase the risk of myocardial infarction. The FDA imposed REMS (Risk Evaluation and Mitigation Strategy) restrictions limiting use, but these restrictions were lifted in 2013 after additional analyses showed the cardiovascular risk concerns were not confirmed in longer-term data. Avandia remains FDA-approved for type 2 diabetes, though many providers still prefer pioglitazone or other agents
Both are thiazolidinediones that improve insulin sensitivity. Pioglitazone (Actos) has been associated with a possible small increase in bladder cancer with long-term use. Rosiglitazone (Avandia) had earlier concerns about myocardial infarction risk. In current practice, pioglitazone is more commonly used than rosiglitazone, but both are now relatively second-line agents in light of newer options (SGLT2 inhibitors, GLP-1 receptor agonists).
Yes. TZDs (both rosiglitazone and pioglitazone) cause fluid retention and can precipitate or worsen heart failure. Avandia is contraindicated in NYHA Class III or IV heart failure and should be used with great caution in any patient with heart failure history. Watch for symptoms of fluid retention — leg swelling, weight gain, shortness of breath — and report them promptly.
Yes. SGLT2 inhibitors (empagliflozin/Jardiance, dapagliflozin/Farxiga, canagliflozin/Invokana) and GLP-1 receptor agonists (semaglutide/Ozempic, dulaglutide/Trulicity, tirzepatide/Mounjaro) are now preferred in many guidelines because of cardiovascular and kidney benefits beyond glucose control. They cost more than generic TZDs but may have important long-term advantages. Discuss with your provider whether one of these might be right for you.
Yes, weight gain is a common side effect of TZDs (rosiglitazone and pioglitazone) — typically 2–5 kg over the first year. Some weight gain is from fluid retention, some from increased adipose tissue. If weight gain is a concern, newer agents like SGLT2 inhibitors and GLP-1 receptor agonists tend to cause weight loss rather than weight g
If denied, we explore alternatives — switching to generic rosiglitazone or generic pioglitazone, or to other classes of diabetes therapy (metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 RAs), the manufacturer’s copay program for commercially insured patients, or independent foundations. If we cannot find a path, you won’t be charged our service fee.
If you are struggling with the high cost of Avandia, our team may be able to help you access assistance programs — or guide you to a more cost-effective diabetes regimen. Check your eligibility today.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.